Completed PHASE4 INTERVENTIONAL 3-arm NCT00536380

Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)

A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)

Sponsor: Organon and Co

Conditions Chronic Idiopathic Urticaria

Interventions 10-mg Desloratadine 20-mg Desloratadine 5-mg Desloratadine

Updated 9 times since 2017 Last updated: May 8, 2024 Started: Sep 30, 2007 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Idiopathic Urticaria, this trial is completed. The trial is conducted by Organon and Co and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2024 — Jul 2024 [monthly]

Completed PHASE4
Mar 2022 — Jun 2024 [monthly]

Completed PHASE4
Dec 2021 — Mar 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.